Randomized, multicenter, double-blind, placebo-controlle

Project: Research project

Description

Randomized, multicenter, double-blind, placebo-controlled, parallel-group Phase III study to investigate the efficacy, safety, and tolerability of 2 different doses of IgPro20 (subcutaneous immunoglobulin) for the treatment
StatusFinished
Effective start/end date1/1/144/30/18

Funding

  • CSL BEHRING GMBH

Fingerprint

Immunoglobulins
Placebos
Safety
Therapeutics
Hizentra